Aazim Siddiqui
Ophthalmology · Portland, ORNPI 1770947723
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,590 of the $13,289 with a category attached, or 64.6%. 20 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 34.2% of the total. 2025 is the largest year on record at $6,222, more than ten times the $13 reported in 2021. Among ophthalmology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 203 payments — averaging $65.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$5K
- AbbVie$2K
- Biotissue Holdings Inc.$1K
- Sun Pharmaceutical Industries Inc.$932
- Mallinckrodt Hospital Products Inc.$672
- Glaukos Corporation$670
- plus $3K from 14 others
What the payments were for
- Consulting fees$2,27517%
- Travel & lodging$2,32317%
- Food & beverage$8,59065%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 37 | $4,540 |
| AbbVie | 34 | $2,449 |
| Biotissue Holdings Inc. | 5 | $1,138 |
| Sun Pharmaceutical Industries Inc. | 33 | $932 |
| Mallinckrodt Hospital Products Inc. | 16 | $672 |
| Glaukos Corporation | 8 | $670 |
| Amgen(2 entities) | 11 | $657 |
| Alcon | 16 | $557 |
| Tarsus Pharmaceuticals, Inc. | 12 | $377 |
| NEW World Medical,inc. | 4 | $302 |
| Rxsight Inc | 2 | $195 |
| Carl Zeiss Meditec USA, Inc. | 1 | $190 |
| Sight Sciences, Inc. | 6 | $181 |
| Harrow Eye, LLC | 5 | $142 |
| Oyster Point Pharma, Inc. | 6 | $111 |
| Dompe US, Inc. | 3 | $88 |
| Rayner Intraocular Lenses Limited | 1 | $27 |
| GSK | 1 | $23 |
| Thea Pharma Inc. | 1 | $20 |
| Oasis Medical, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TENEO$1,921
- enVista Aspire IOL$1,781
- STELLARIS ELITE$1,781
- XEN GLAUCOMA TREATMENT SYSTEM$1,154
- DURYSTA$567
- TEPEZZA$407
- iDoseTR$400
- CEQUA$348
- ACTHAR$269
- Prokera$193
- AmnioGraft$193
- EQ Workplace$190
- RXSIGHT CONTACT LENS$163
- RXSIGHT INJECTOR CARTRIDGE$163
- RXSIGHT INJECTOR HANDPIECE$163
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$163
- LIGHT ADJUSTABLE LENS (LAL)$163
- Rocklatan$130
- TRYPTYR$125
- MIEBO$121
How this compares
$13,289 in reported general payments places this provider in the 95th percentile of 248 ophthalmology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 29 | $35,255 |
| RestasisCyclosporine | 19 | $28,784 |
| Prednisolone Acetate | 163 | $11,714 |
| MieboPerfluorohexyloctane/Pf | 16 | $11,165 |
| LumiganBimatoprost | 13 | $9,558 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $4,859 |
| Brimonidine Tartrate | 36 | $4,820 |
| MoxifloxacinMoxifloxacin Hcl | 121 | $2,155 |
| Ketorolac Tromethamine | 91 | $1,864 |
| Latanoprost | 95 | $1,674 |
| Difluprednate | 15 | $1,339 |
| Timolol Maleate | 48 | $803 |
| Dorzolamide Hcl | 13 | $328 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 27 | $305 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 13 | $276 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $4,540 | $46,42145 claims |
| AbbVieRestasis, Lumigan | $2,449 | $38,34232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 248 ophthalmology providers in Oregon.
Other ophthalmology in Portland
- Mark PennesiPortland$56K
- Rene ChoiPortland$21K
- Richard WeleberPortland$14K
- Richard StutzmanPortland$10K
- Matthew KaufmanPortland$8K
- Paul YangPortland$7K
- Monia RedingPortland$5K
- Richard DreyerPortland$5K
- Andrea YongePortland$4K
- Janani SingaraveluPortland$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.